Merck Serono points finger at UK oncologists for personalised meds lag
This article was originally published in Clinica
The UK is lagging far behind Europe in testing cancer patients for biomarkers, with oncologists who are too set in their ways to test for and prescribe innovative drugs the main problem, according to Merck Serono's director of oncology, Rob Drury-Dryden.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.